4M Therapeutics Inc.: Funding, Investors & Team (Sep 2026)
4M Therapeutics Inc. (4MTx) is developing targeted therapies for central nervous system (CNS) disorders. Our discovery platform was developed at Harvard, MIT and the University of Washington to uncover how drugs like lithium enhance the health of living human brain cells – and then to design better alternatives. Pre-clinical data show that our lead asset 4MT2001 has the potential to provide a better combination of efficacy and safety than lithium for the treatment of bipolar disorder (BPD). Clinical trials will begin in early 2025 as we seek to address a $6 billion US market. Beyond BPD, our pipeline has the potential to address Alzheimer’s disease, frontal temporal dementia, and other brain disorders with broad clinical, commercial, and partnering potential. 4MTx is led by CEO Pablo Lapuerta, who has developed and launched multiple drugs. He introduced into clinical trials the first targeted CNS kinase inhibitor to show successful proof-of-concept data. Board Chair Don Hayden was previously President of Global Pharmaceuticals at Bristol Myers-Squibb and led the development and commercialization of CNS blockbuster Abilify (peak annual sales > $6B). Board member Dr. Lawrence Goldstein co-founded publicly-traded Cytokinetics and is professor emeritus at UC San Diego with extensive CNS experience.
4M Therapeutics Inc. has raised $120k across 2 funding rounds on record, the most recent a Seed announced in Aug 2025.
4M Therapeutics Inc. Company Profile and Key Stats
Latest funding round on record: Aug 2025.
4M Therapeutics Inc. Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
4M Therapeutics Inc. raised $120k in an undisclosed round announced in Nov 2024.
9 months later, a Seed was announced in Aug 2025 with no disclosed amount.
4M Therapeutics Inc. Founders and Leadership Team
Contact details for the 4M Therapeutics Inc. team: 1 of 2 have an email address on file.
Start 14-day free trial →4M Therapeutics Inc. Funding Compared to Other Biotechnology Startups
Funded Startups Like 4M Therapeutics Inc. in Biotechnology and Princeton
Companies Similar to 4M Therapeutics Inc.
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
4M Therapeutics Inc. Funding FAQs
What does 4M Therapeutics Inc. do?
4M Therapeutics Inc. (4MTx) is developing targeted therapies for central nervous system (CNS) disorders. Our discovery platform was developed at Harvard, MIT and the University of Washington to uncover how drugs like lithium enhance the health of living human brain cells – and then to design better alternatives. Pre-clinical data show that our lead asset 4MT2001 has the potential to provide a better combination of efficacy and safety than lithium for the treatment of bipolar disorder (BPD). Clinical trials will begin in early 2025 as we seek to address a $6 billion US market. Beyond BPD, our pipeline has the potential to address Alzheimer’s disease, frontal temporal dementia, and other brain disorders with broad clinical, commercial, and partnering potential. 4MTx is led by CEO Pablo Lapuerta, who has developed and launched multiple drugs. He introduced into clinical trials the first targeted CNS kinase inhibitor to show successful proof-of-concept data. Board Chair Don Hayden was previously President of Global Pharmaceuticals at Bristol Myers-Squibb and led the development and commercialization of CNS blockbuster Abilify (peak annual sales > $6B). Board member Dr. Lawrence Goldstein co-founded publicly-traded Cytokinetics and is professor emeritus at UC San Diego with extensive CNS experience.
How much funding has 4M Therapeutics Inc. raised?
4M Therapeutics Inc. has raised $120k across 2 rounds on record.
When did 4M Therapeutics Inc. last raise funding?
4M Therapeutics Inc.'s most recent funding round on record was announced in Aug 2025. The amount was not disclosed.
Who founded 4M Therapeutics Inc.?
FundedIQ lists Ben Williams (Founder), Pablo Lapuerta (Founder) at 4M Therapeutics Inc..
Where is 4M Therapeutics Inc. headquartered?
4M Therapeutics Inc. is based in Princeton, New Jersey, United States.
How many employees does 4M Therapeutics Inc. have?
4M Therapeutics Inc. is in the 1-10 employee band.
About FundedIQ's 4M Therapeutics Inc. Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for 4M Therapeutics Inc. is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.